New Delhi, Feb 6 (UNI) Ranbaxy Laboratories Ltd (RLL) today said it has received approval from the US Food and Drug Administration (FDA) to manufacture and market Cefuroxime Axetil Suspension.
The medicine is prescribed for the treatment of pediatric patients suffering from mild to moderate infections like Tonsillitis and Impetigo.
The company will manufacture the medicine's oral suspension USP, 125 mg/5mL and 250 mg/5mL, which will be the first generic formulation on the market, a company statement said.
Total annual market sales for the drug stands at 28.7 million dollars, the statement added.
UNI SG PBB HS1723